Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.56 |
| ▸ | ADH1C | P00326 | 1/20 | 0.56 |
| ▸ | ADH1A | P07327 | 1/20 | 0.56 |
| ▸ | ADH4 | P08319 | 1/20 | 0.56 |
| ▸ | ADH7 | P40394 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863341 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL871690 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6898195 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL23340664 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8571264 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL24631739 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL668931 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11851660 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9203991 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6269026 | 1.00 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| WO-2024050352-A2 | Branched Lipid Compositions, Lipid Nanoparticles (LNPs) Comprising the Same, and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023211938-A1 | METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE | CYTEIR THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11702432-B2 | Method of making an organoaminosilane | DOW SILICONES CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230036244-A1 | NON-FLAMMABLE POLYMERIC ELECTROLYTE WITH WIDE OPERATIONAL TEMPERATURE RANGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-02 | — | — | US | disclosed |
| EP-3400255-B1 | PROCESS FOR PREPARING GRAFT COPOLYMER COMPRISING POLYETHYLENE | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2022-04-20 | — | — | EP | disclosed |
| EP-3390410-B1 | METHODS OF MAKING HIGH PURITY TRISILYLAMINE | NATA SEMICONDUCTOR MAT CO LTD (CN) | 2022-02-02 | — | — | EP | disclosed |
| WO-2022015656-A1 | CAMPTOTHECIN ANALOGS CONJUGATED TO A GLUTAMINE RESIDUE IN A PROTEIN, AND THEIR USE | REGENERON PHARMACEUTICALS, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-11111256-B2 | High purity trisilylamine, methods of making, and use | JIANGSU NATA OPTO-ELECTRONIC MATERIALS CO. LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-108602839-B | A process for preparing an organoaminosilane; method for producing silylamines from organoaminosilanes | 南大光电半导体材料有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| US-20190352315-A1 | METHOD FOR MAKING AN ORGANOAMINOSILANE; A METHOD FOR MAKING A SILYLAMINE FROM THE ORGANOAMINOSILANE | DOW SILICONES CORPORATION (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3390411-A1 | METHOD FOR MAKING AN ORGANOAMINOSILANE; A METHOD FOR MAKING A SILYLAMINE FROM THE ORGANOAMINOSILANE | Dow Corning Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3390410-A1 | HIGH PURITY TRISILYLAMINE, METHODS OF MAKING, AND USE | Dow Corning Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| WO-2017106632-A1 | METHOD FOR MAKING AN ORGANOAMINOSILANE; A METHOD FOR MAKING A SILYLAMINE FROM THE ORGANOAMINOSILANE | DOW CORNING CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106625-A1 | HIGH PURITY TRISILYLAMINE, METHODS OF MAKING, AND USE | DOW CORNING CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160130282-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2016-05-12 | — | — | US | disclosed |
| WO-2014086751-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-CYCLOHEXANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20090180914-A1 | Interconnect material and interconnect formation method | HITACHI, LTD. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130282-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | HNMT, HRH2, HRH4 | ADH1B 429/4885ADH1C 262/4885ADH1A 356/4885 |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | ADH1B 245/4885ADH1C 922/4885ADH1A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.